Neurocrine biosciences to present new data from phase 2 study of osavampator in adults with major depressive disorder at 38th annual psych congress 2025

Additional data from savitri™ study expand on top-line results announced in april 2024 savitri poster presentation chosen as finalist for psych congress poster awards san diego , sept. 16, 2025 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced that it will present new data from the phase 2 savitri study of osavampator in adults with major depressive disorder at psych congress 2025, taking place september 17-21 in san diego.
NBIX Ratings Summary
NBIX Quant Ranking